Fei Zhou

TL;DR: Conventionally fractionated radiotherapy in combination with anti–PD‐L1 antibody shows a synergistic antitumor immunity in NSCLC and PD‐L 1 expression may be a significant clinical predictive factor for treatment response to radiotherapeutic treatment inNSCLC.

TL;DR: In this paper, the authors analyzed 42 tissue biopsy samples from stage III/IV NSCLC patients by single cell RNA sequencing and presented the large scale, single cell resolution profiles of advanced NSCLCs.

TL;DR: The current study showed that consolidative LAT to all metastatic sites was a feasible option for patients with EGFR‐mutant oligometastatic NSCLC during first‐line EGFR–tyrosine kinase inhibitor (TKI) treatment, with significantly improved PFS and OS compared with consolidatives LAT to partial sites or observation alone.

TL;DR: The addition of WBRT to EGFR TKIs did not appear to have survival benefit superior to that of EGFRTKIs alone in with EGFR‐mutant NSCLC with BM, and W BRT also did not bring additional benefit to chemotherapy in patients with BM and EGFR of wild‐type or unknown status.

TL;DR: An overview of East Asian experience in the treatment of advanced, never-smoking lung cancer is provided, focusing on etiologic factors in the development of LCINS, targeted therapy for never-smokers with adenocarcinoma, distinct characteristics of never-Smokers with lung SQCC and SCLC, and the role of immunotherapy in never- Smokers with NSCLC.